Novo Nordisk: to present haemophilia data at congress.
(CercleFinance.com) - Denmark's Novo Nordisk plans to present a whole series of data from its haemophilia treatment portfolio at an upcoming conference, the company said on Monday.
The firm announced today that data from 35 abstracts will be presented at the International Society on Thrombosis and Haemostasis (ISTH) congress, which will be held from 8 July to 13 July in Germany.
Data to be presented includes evaluation of safety and establishment of pharmacokinetic (PK) and pharmacodynamic (PD) relationship of concizumab in haemophilia A patients.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The firm announced today that data from 35 abstracts will be presented at the International Society on Thrombosis and Haemostasis (ISTH) congress, which will be held from 8 July to 13 July in Germany.
Data to be presented includes evaluation of safety and establishment of pharmacokinetic (PK) and pharmacodynamic (PD) relationship of concizumab in haemophilia A patients.
Copyright (c) 2017 CercleFinance.com. All rights reserved.